Table 2. General features of 160 patients with non-fibrotic pulmonary sarcoidosis classified as having a self-limited or persistent course.a .
| Feature | Group | p | |
|---|---|---|---|
| Self-limited course | Persistent course | ||
| (n = 85) | (n = 75) | ||
| Female/male | 55 (65)/30 (35) | 46 (61)/29 (39) | 0.74 |
| Age, years | 48.2 ± 12.8 | 48.5 ± 9.9 | 0.64 |
| Time to diagnosis: early/delayed | 60 (71)/25 (29) | 38 (51)/37 (49) | 0.01 |
| Follow-up, months | 76 [41, 114] | 98 [40, 163] | 0.20 |
| Smoking (current or former smoker) | 23 (27) | 25 (33) | 0.75 |
| Dyspnea | 23 (27) | 33 (44) | 0.03 |
| Weight loss | 37 (44) | 32 (43) | 1.00 |
| Fever | 15 (18) | 15 (20) | 0.84 |
| Erythema nodosum | 10 (12) | 6 (8) | 0.43 |
| Tuberculosis treatment | 10 (12) | 23 (31) | < 0.01 |
| Radiological staging | |||
| I | 27 (32) | 11 (15) | 0.04 |
| II | 46 (54) | 51 (68) | |
| III | 12 (14) | 13 (17) | |
| Reduced FVC | 17 (20) | 30 (40) | < 0.01 |
| FEV1/FVC ratio | 0.79 ± 0.09 | 0.79 ± 0.10 | 0.72 |
| Two or more relevant extrathoracic involvements | 4 (5) | 13 (17) | 0.01 |
| Pharmacological treatment | 38 (45) | 75 (100) | < 0.01 |
a
Values expressed as n (%), mean ± SD, or median [Q1, Q3].